Global Drug Treatment for Respiratory Disease 麻豆原创 Research Report 2024

Publication ID:

PB505246768

Publication Date:

May 22, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Respiratory diseases may be caused by infection, by smoking tobacco, or by breathing in secondhand tobacco smoke, radon, asbestos, or other forms of air pollution. Respiratory diseases include asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pneumonia, and lung cancer.
The global Drug Treatment for Respiratory Disease market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
Nebulization inhalation therapy is an important treatment method for respiratory system-related diseases. Compared with oral administration, intramuscular injection and intravenous administration, aerosol inhalation therapy has the advantages of rapid onset of action, good curative effect, fewer systemic adverse reactions, and does not require the patient's deliberate cooperation because the drug directly acts on the target organ. It has been adopted domestically. Widely used outside.
This report aims to provide a comprehensive presentation of the global market for Drug Treatment for Respiratory Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug Treatment for Respiratory Disease.
The Drug Treatment for Respiratory Disease market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drug Treatment for Respiratory Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drug Treatment for Respiratory Disease companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
GSK
AstraZeneca
Boehringer Ingelheim
Novartis
Mylan
Vertex Pharmaceuticals
F. Hoffman La Roche
Teva Pharmaceuticals
Cipla
Fibrogen
Liminal Biosciences
PharmAkea Therapeutics
IQVIA
Segment by Type
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Lung Cancer
Other Diseases
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drug Treatment for Respiratory Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Drug Treatment for Respiratory Disease 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Asthma
1.2.3 Chronic Obstructive Pulmonary Disease (COPD)
1.2.4 Lung Cancer
1.2.5 Other Diseases
1.3 麻豆原创 by Application
1.3.1 Global Drug Treatment for Respiratory Disease 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drug Treatment for Respiratory Disease 麻豆原创 Perspective (2019-2030)
2.2 Global Drug Treatment for Respiratory Disease Growth Trends by Region
2.2.1 Global Drug Treatment for Respiratory Disease 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drug Treatment for Respiratory Disease Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Drug Treatment for Respiratory Disease Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Drug Treatment for Respiratory Disease 麻豆原创 Dynamics
2.3.1 Drug Treatment for Respiratory Disease Industry Trends
2.3.2 Drug Treatment for Respiratory Disease 麻豆原创 Drivers
2.3.3 Drug Treatment for Respiratory Disease 麻豆原创 Challenges
2.3.4 Drug Treatment for Respiratory Disease 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drug Treatment for Respiratory Disease Players by Revenue
3.1.1 Global Top Drug Treatment for Respiratory Disease Players by Revenue (2019-2024)
3.1.2 Global Drug Treatment for Respiratory Disease Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Drug Treatment for Respiratory Disease 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Drug Treatment for Respiratory Disease Revenue
3.4 Global Drug Treatment for Respiratory Disease 麻豆原创 Concentration Ratio
3.4.1 Global Drug Treatment for Respiratory Disease 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug Treatment for Respiratory Disease Revenue in 2023
3.5 Global Key Players of Drug Treatment for Respiratory Disease Head office and Area Served
3.6 Global Key Players of Drug Treatment for Respiratory Disease, Product and Application
3.7 Global Key Players of Drug Treatment for Respiratory Disease, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug Treatment for Respiratory Disease Breakdown Data by Type
4.1 Global Drug Treatment for Respiratory Disease Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Drug Treatment for Respiratory Disease Forecasted 麻豆原创 Size by Type (2025-2030)
5 Drug Treatment for Respiratory Disease Breakdown Data by Application
5.1 Global Drug Treatment for Respiratory Disease Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Drug Treatment for Respiratory Disease Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Drug Treatment for Respiratory Disease 麻豆原创 Size (2019-2030)
6.2 North America Drug Treatment for Respiratory Disease 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drug Treatment for Respiratory Disease 麻豆原创 Size by Country (2019-2024)
6.4 North America Drug Treatment for Respiratory Disease 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drug Treatment for Respiratory Disease 麻豆原创 Size (2019-2030)
7.2 Europe Drug Treatment for Respiratory Disease 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drug Treatment for Respiratory Disease 麻豆原创 Size by Country (2019-2024)
7.4 Europe Drug Treatment for Respiratory Disease 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drug Treatment for Respiratory Disease 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Drug Treatment for Respiratory Disease 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drug Treatment for Respiratory Disease 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Drug Treatment for Respiratory Disease 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drug Treatment for Respiratory Disease 麻豆原创 Size (2019-2030)
9.2 Latin America Drug Treatment for Respiratory Disease 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drug Treatment for Respiratory Disease 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Drug Treatment for Respiratory Disease 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drug Treatment for Respiratory Disease 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Drug Treatment for Respiratory Disease 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drug Treatment for Respiratory Disease 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Drug Treatment for Respiratory Disease 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Drug Treatment for Respiratory Disease Introduction
11.1.4 GSK Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.1.5 GSK Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Drug Treatment for Respiratory Disease Introduction
11.2.4 AstraZeneca Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.2.5 AstraZeneca Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Details
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Drug Treatment for Respiratory Disease Introduction
11.3.4 Boehringer Ingelheim Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Drug Treatment for Respiratory Disease Introduction
11.4.4 Novartis Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Mylan
11.5.1 Mylan Company Details
11.5.2 Mylan Business Overview
11.5.3 Mylan Drug Treatment for Respiratory Disease Introduction
11.5.4 Mylan Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.5.5 Mylan Recent Development
11.6 Vertex Pharmaceuticals
11.6.1 Vertex Pharmaceuticals Company Details
11.6.2 Vertex Pharmaceuticals Business Overview
11.6.3 Vertex Pharmaceuticals Drug Treatment for Respiratory Disease Introduction
11.6.4 Vertex Pharmaceuticals Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.6.5 Vertex Pharmaceuticals Recent Development
11.7 F. Hoffman La Roche
11.7.1 F. Hoffman La Roche Company Details
11.7.2 F. Hoffman La Roche Business Overview
11.7.3 F. Hoffman La Roche Drug Treatment for Respiratory Disease Introduction
11.7.4 F. Hoffman La Roche Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.7.5 F. Hoffman La Roche Recent Development
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Company Details
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals Drug Treatment for Respiratory Disease Introduction
11.8.4 Teva Pharmaceuticals Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.8.5 Teva Pharmaceuticals Recent Development
11.9 Cipla
11.9.1 Cipla Company Details
11.9.2 Cipla Business Overview
11.9.3 Cipla Drug Treatment for Respiratory Disease Introduction
11.9.4 Cipla Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.9.5 Cipla Recent Development
11.10 Fibrogen
11.10.1 Fibrogen Company Details
11.10.2 Fibrogen Business Overview
11.10.3 Fibrogen Drug Treatment for Respiratory Disease Introduction
11.10.4 Fibrogen Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.10.5 Fibrogen Recent Development
11.11 Liminal Biosciences
11.11.1 Liminal Biosciences Company Details
11.11.2 Liminal Biosciences Business Overview
11.11.3 Liminal Biosciences Drug Treatment for Respiratory Disease Introduction
11.11.4 Liminal Biosciences Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.11.5 Liminal Biosciences Recent Development
11.12 PharmAkea Therapeutics
11.12.1 PharmAkea Therapeutics Company Details
11.12.2 PharmAkea Therapeutics Business Overview
11.12.3 PharmAkea Therapeutics Drug Treatment for Respiratory Disease Introduction
11.12.4 PharmAkea Therapeutics Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.12.5 PharmAkea Therapeutics Recent Development
11.13 IQVIA
11.13.1 IQVIA Company Details
11.13.2 IQVIA Business Overview
11.13.3 IQVIA Drug Treatment for Respiratory Disease Introduction
11.13.4 IQVIA Revenue in Drug Treatment for Respiratory Disease Business (2019-2024)
11.13.5 IQVIA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

GSK
AstraZeneca
Boehringer Ingelheim
Novartis
Mylan
Vertex Pharmaceuticals
F. Hoffman La Roche
Teva Pharmaceuticals
Cipla
Fibrogen
Liminal Biosciences
PharmAkea Therapeutics
IQVIA

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.